Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
ALKS Alkermes
25.200
+0.420+1.69%
Post Mkt Price
25.2000.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-14.21% 252.36M -9.05% 276.22M 10.78% 278.55M 13.00% 1.17B
Operating revenue
-14.21% 252.36M -9.05% 276.22M 10.78% 278.55M 13.00% 1.17B
Cost of revenue
-10.07% 151.06M 0.42% 151.23M 13.37% 151.11M 5.41% 603.91M
Gross profit
-19.71% 101.3M -18.37% 124.99M 7.86% 127.43M 22.32% 569.84M
Operating expense
11.05% 161.94M 7.23% 159.44M 14.45% 154.02M 3.60% 599.13M
Selling and administrative expenses
12.16% 152.78M 8.04% 150.38M 15.89% 145.05M 4.11% 560.98M
-Selling and marketing expense
10.11% 96.9M 11.20% 95.3M 20.70% 96.2M -- --
-General and administrative expense
15.90% 55.88M 2.97% 55.08M 7.44% 48.85M -- --
Depreciation amortization depletion
-4.67% 9.17M -4.68% 9.07M -4.68% 8.97M -3.31% 38.15M
-Depreciation and amortization
-4.67% 9.17M -4.68% 9.07M -4.68% 8.97M -3.31% 38.15M
Operating profit
-208.46% -60.64M -879.39% -34.46M -61.79% -26.59M 73.95% -29.29M
Net non-operating interest income expense
33.32% -1.31M 17.43% -1.47M 42.79% -1.78M -418.60% -8.81M
Non-operating interest income
378.42% 2.24M 43.82% 896K -33.68% 573K -65.40% 2.41M
Non-operating interest expense
45.75% 3.55M -1.58% 2.37M -40.81% 2.35M 29.56% 11.22M
Other net income (expense)
-10.33% -5.41M -11.20% 2.68M -1,979.77% -16.64M -106.87% -1.21M
Special income (charges)
31.61% -3.55M -73.15% 870K -1,591.94% -19.07M -136.17% -1.43M
-Less:Restructuring and merger&acquisition
-31.61% 3.55M 73.15% -870K 1,591.94% 19.07M 136.17% 1.43M
Other non- operating income (expenses)
-746.18% -1.86M 915.32% 1.81M 718.58% 2.43M -98.39% 219K
Income before tax
-153.88% -67.37M -687.98% -33.25M -141.24% -45M 59.28% -39.31M
Income tax
-238.36% -3.39M -194.62% -3.11M -341.57% -9.1M -38.12% 8.86M
Net income
-120.69% -63.97M -1,374.79% -30.14M -60.15% -35.9M 56.55% -48.17M
Net income continuous Operations
-120.69% -63.97M -1,374.79% -30.14M -60.15% -35.9M 56.55% -48.17M
Minority interest income
Net income attributable to the parent company
-120.69% -63.97M -1,374.79% -30.14M -60.15% -35.9M 56.55% -48.17M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-120.69% -63.97M -1,374.79% -30.14M -60.15% -35.9M 56.55% -48.17M
Basic earnings per share
-116.67% -0.39 -1,900.00% -0.18 -57.14% -0.22 57.14% -0.3
Diluted earnings per share
-116.67% -0.39 -1,900.00% -0.18 -57.14% -0.22 57.14% -0.3
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
CEO: Mr. Richard F. Pops
Market: NASDAQ
Listing Date: 09/19/2011
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist